Non-eosinophilic asthma: current perspectives.

Asthma Allergy. 2018 Oct 29;11:267-281. doi: 10.2147/JAA.S153097. eCollection 2018.

Abstract

Although non-eosinophilic asthma (NEA) is not the best known and most prevalent asthma phenotype, its importance cannot be underestimated. NEA is characterized by airway inflammation with the absence of eosinophils, subsequent to activation of non-predominant type 2 immunologic pathways. This phenotype, which possibly includes several not well-defined subphenotypes, is defined by an eosinophil count <2% in sputum. NEA has been associated with environmental and/or host factors, such as smoking cigarettes, pollution, work-related agents, infections, and obesity. These risk factors, alone or in conjunction, can activate specific cellular and molecular pathways leading to non-type 2 inflammation. The most relevant clinical trait of NEA is its poor response to standard asthma treatments, especially to inhaled corticosteroids, leading to a higher severity of disease and to difficult-to-control asthma. Indeed, NEA constitutes about 50% of severe asthma cases. Since most current and forthcoming biologic therapies specifically target type 2 asthma phenotypes, such as uncontrolled severe eosinophilic or allergic asthma, there is a dramatic lack of effective treatments for uncontrolled non-type 2 asthma. Research efforts are now focusing on elucidating the phenotypes underlying the non-type 2 asthma, and several studies are being conducted with new drugs and biologics aiming to develop effective strategies for this type of asthma, and various immunologic pathways are being scrutinized to optimize efficacy and to abolish possible adverse effects.

Icon for PubMed Central

(You must be logged in to add and reply comments)

Interasma on Twitter

Interasma RT @Aller_MD: iMedicalApps: This Week's Top Picks for Apple and Android https://t.co/KQgu08Rpzj
58mreplyretweetfavorite
Interasma RT @Aller_MD: HIV vaccine protects non-human primates from infection https://t.co/6b7m7ivwdY
58mreplyretweetfavorite
Interasma RT @Aller_MD: Subfertility linked to increased #asthma risk in offspring https://t.co/pRztkOtpoy
58mreplyretweetfavorite
Interasma RT @Aller_MD: The latest Allergy, Asthma & Immunology! https://t.co/x6oPcvzlZg #cta_journal #immune
58mreplyretweetfavorite
Interasma RT @Aller_MD: The latest Allergists on Social Media! https://t.co/e71Ef1ORZS Thanks to @EAACI_HQ #cta_journal #immune
58mreplyretweetfavorite

Editor: Juan C. Ivancevich, MD

Copyright © Interasma 2003-2017  •  Terms of Use  •  Privacy Policy  •  Contact Us  •  Sitemap

Powered by FREI SA

InterAsma